1. Home
  2. HOUR vs ACET Comparison

HOUR vs ACET Comparison

Compare HOUR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

HOLD

Current Price

$1.93

Market Cap

63.3M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.24

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
ACET
Founded
2015
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
69.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
HOUR
ACET
Price
$1.93
$7.24
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
14.3K
182.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
128.57
59.82
EPS
0.07
N/A
Revenue
$138,252,861.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.86
N/A
Revenue Growth
4.64
N/A
52 Week Low
$1.10
$0.45
52 Week High
$6.84
$9.05

Technical Indicators

Market Signals
Indicator
HOUR
ACET
Relative Strength Index (RSI) 56.53 53.18
Support Level $1.73 $0.62
Resistance Level $1.95 $8.46
Average True Range (ATR) 0.08 0.52
MACD 0.01 -0.07
Stochastic Oscillator 48.76 73.50

Price Performance

Historical Comparison
HOUR
ACET

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: